Talk:Lenacapavir

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

AIDS Low‑importance

	This article is part of WikiProject AIDS, an attempt to build a comprehensive, detailed, and accessible guide to AIDS, HIV, and related topics on Wikipedia. If you would like to participate in the project, you can choose to edit this article, or visit the project page for more information.AIDSWikipedia:WikiProject AIDSTemplate:WikiProject AIDSAIDS articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lenacapavir.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Want: pharmacokinetics

This drug has just made the news from a twice-yearly trial. It probably has some really interesting pharmacokinetics; https://liverpool-hiv-hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/229/original/HIV_FactSheet_LEN_2022_Oct.pdf?1665666788 (a summary of the official Summary of Product Characteristics — cite the official thing!) does show some long half-lives. —Artoria 2e5 🌉 05:54, 21 June 2024 (UTC)[reply]

Also poorly soluble in water so given as a PEG suspension. Wait, did it say picomolar? (https://pubmed.ncbi.nlm.nih.gov/37917742/) —Artoria 2e5 🌉 05:56, 21 June 2024 (UTC)[reply]

@Artoria2e5: I wanted to update the page to reflect the recent impressive efficacy data, but all media sources seem to reference Gilead's press release. Is it best to wait until there's a more detailed press release ("More detailed data from PURPOSE 1 will be presented at a future conference.") and/or an official record of the end of the blinded phase of the trial? RFZYNSPY ^talk 19:22, 21 June 2024 (UTC)[reply]

It could be. Let’s at least wait for a preprint on that. Artoria 2e5 🌉 07:25, 22 June 2024 (UTC)[reply]